Arrowhead Pharmaceuticals, Inc.
ARWR stock score: 47/100
$58.92 · +2.95% · Scored Oct 20, 2026
- Technical
- 53
- Fundamental
- 41
- News
- 56
The reading
Arrowhead Pharmaceuticals (ARWR) scores 47 out of 100, which reads weak, higher than 54% of Healthcare stocks and 34% of the 4,166 US stocks we score.
The composite is technicals and fundamentals weighted equally: technicals read 53, fundamentals 41.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Price to Book Ratio at 0 weighs the most against it.
On the daily chart, trend-following indicators average 26 and contrarian oscillators 71 — a split worth reading before trusting the technical total.
News sentiment is neutral at 56; it is shown, not counted in the composite.
Since Jul 25, 2026 the composite has ranged from 45 to 73, and it is down 26 points over the period.
What’s driving the score
The strongest and weakest of the scorers that count toward ARWR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
41Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
- Fund Ownership100
Fund ownership tracks institutional investor holdings and changes.
Holding it back
- Price to Book Ratio0
Price-to-Book ratio compares market value to book value.
- Operating Margins0
Operating margins measure profitability after operating expenses.
- Profit Margins0
Profit margins show what percentage of revenue becomes profit.
38 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
32Pulling it up
- Money Flow Index (14)100
Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.
- 52-Week Change100
The price change over the last 52 weeks.
- RSI (14)91
Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.
Holding it back
- Performance vs SPY0
Performance versus SPY compares the stock's returns to the S&P 500 index.
- Ichimoku Cloud0
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
- SMA 1000
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 56
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 58 | 1 |
| Daily | 32 | 3 |
| Weekly | 47 | 2 |
| Monthly | 69 | 2 |
| Quarterly | 70 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Oct 20, 2026 | 47 |
| Oct 19, 2026 | 46 |
| Oct 18, 2026 | 45 |
| Oct 17, 2026 | 45 |
| Oct 16, 2026 | 45 |
| Oct 15, 2026 | 46 |
| Oct 14, 2026 | 46 |
| Oct 13, 2026 | 46 |
| Oct 12, 2026 | 46 |
| Oct 11, 2026 | 47 |
| Oct 10, 2026 | 47 |
| Oct 9, 2026 | 47 |
| Oct 8, 2026 | 46 |
| Oct 7, 2026 | 46 |
| Oct 6, 2026 | 45 |
| Oct 5, 2026 | 45 |
| Oct 4, 2026 | 47 |
| Oct 3, 2026 | 47 |
| Oct 2, 2026 | 46 |
| Oct 1, 2026 | 46 |
| Sep 30, 2026 | 46 |
| Sep 29, 2026 | 48 |
| Sep 28, 2026 | 47 |
| Sep 27, 2026 | 47 |
| Sep 26, 2026 | 47 |
| Sep 25, 2026 | 46 |
| Sep 24, 2026 | 47 |
| Sep 23, 2026 | 48 |
| Sep 22, 2026 | 49 |
| Sep 21, 2026 | 48 |
| Sep 20, 2026 | 47 |
| Sep 19, 2026 | 47 |
| Sep 18, 2026 | 47 |
| Sep 17, 2026 | 47 |
| Sep 16, 2026 | 46 |
| Sep 15, 2026 | 48 |
| Sep 14, 2026 | 51 |
| Sep 13, 2026 | 52 |
| Sep 12, 2026 | 52 |
| Sep 11, 2026 | 51 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 51 |
| Sep 8, 2026 | 55 |
| Sep 7, 2026 | 54 |
| Sep 6, 2026 | 54 |
| Sep 5, 2026 | 54 |
| Sep 4, 2026 | 54 |
| Sep 3, 2026 | 55 |
| Sep 2, 2026 | 54 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 51 |
| Aug 30, 2026 | 53 |
| Aug 29, 2026 | 53 |
| Aug 28, 2026 | 53 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 56 |
| Aug 25, 2026 | 56 |
| Aug 24, 2026 | 53 |
| Aug 23, 2026 | 54 |
| Aug 22, 2026 | 54 |
| Aug 20, 2026 | 57 |
| Aug 19, 2026 | 59 |
| Aug 18, 2026 | 58 |
| Aug 17, 2026 | 59 |
| Aug 16, 2026 | 58 |
| Aug 15, 2026 | 58 |
| Aug 14, 2026 | 58 |
| Aug 13, 2026 | 58 |
| Aug 12, 2026 | 59 |
| Aug 11, 2026 | 60 |
| Aug 10, 2026 | 60 |
| Aug 9, 2026 | 59 |
| Aug 8, 2026 | 59 |
| Aug 7, 2026 | 60 |
| Aug 6, 2026 | 56 |
| Aug 5, 2026 | 57 |
| Aug 3, 2026 | 57 |
| Aug 2, 2026 | 57 |
| Jul 31, 2026 | 73 |
| Jul 30, 2026 | 71 |
| Jul 29, 2026 | 71 |
| Jul 28, 2026 | 73 |
| Jul 27, 2026 | 73 |
| Jul 26, 2026 | 73 |
| Jul 25, 2026 | 73 |
Key facts
- Market cap
- $8.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.30
- Risk grade (1–10)
- 7
- Next earnings
- Nov 24, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| CYTK Cytokinetics | $8.9B | 46 |
| CAI Caris Life Sciences | $8.8B | 58 |
| SYRE Spyre Therapeutics | $8.5B | 51 |
| AXSM Axsome Therapeutics | $8.4B | 43 |
| TGTX TG Therapeutics | $8.3B | 67 |
| ABVX ABIVAX Société Anonyme | $8.1B | 38 |
Questions
What is ARWR's stock score today?
ARWR scores 47/100 (Weak) as of Oct 20, 2026: technical 53, fundamental 41, and news sentiment 56, which is shown but not counted. Scores are recomputed every night.
Is ARWR a buy?
The score is not a buy or sell recommendation. A 47 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ARWR score calculated?
100 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.